Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.74 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.74 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7611790 | 0.92 | CHRM1 (0.70) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Pyridine SCHEMBL27548875 | 0.91 | CHRM1 (0.64) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL4031440 | 0.89 | CHRM4 (0.76) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL23370707 | 0.88 | CHRM4 (0.74) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL6607269 | 0.88 | CHRM4 (0.74) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6915575 | 0.86 | CHRM4 (0.67) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6914130 | 0.84 | CHRM4 (0.69) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6913185 | 0.84 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL7900811 | 0.84 | CHRM4 (0.97) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6915579 | 0.84 | CHRM4 (0.90) | CHRM1CHRM4CHRM2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | claimed |
| EP-0866702-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-09-30 | — | — | EP | claimed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | claimed |
| US-5712297-A | COGNITION ACTIVATORS; ALZHEIMER*S DISEASE | NOVO NORDISK A/S (DK) | 1998-01-27 | — | — | US | claimed |
| WO-1997020556-A9 | METHOD FOR TREATING PAIN | — | 1997-10-02 | — | — | WO | claimed |
| WO-1997020556-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | claimed |
| WO-1996013168-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | claimed |
| EP-0709095-A2 | Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| EP-0384288-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1995-05-24 | — | — | EP | claimed |
| EP-0384288-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-08-29 | — | — | EP | claimed |
| JP-2255679-A | — | — | None | — | — | JP | disclosed |
| WO-2021097427-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-1996013167-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0709094-A2 | Method for treating anxiety using a tetrahydropyridine oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0709095-A2 | Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| US-5488056-A | 1,2,5-THIADIAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-01-30 | — | — | US | disclosed |
| JP-H02255679-A | PIPERIDINE COMPOUND, ITS PREPARATION AND USE THEREOF | FERROSAN:AS | 1990-10-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CHRM1 24/4885CHRM4 17/4885CHRM2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.